326 related articles for article (PubMed ID: 28566530)
1. Rationale for the development of alternative forms of androgen deprivation therapy.
Kumari S; Senapati D; Heemers HV
Endocr Relat Cancer; 2017 Aug; 24(8):R275-R295. PubMed ID: 28566530
[TBL] [Abstract][Full Text] [Related]
2. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.
Liu S; Kumari S; Hu Q; Senapati D; Venkadakrishnan VB; Wang D; DePriest AD; Schlanger SE; Ben-Salem S; Valenzuela MM; Willard B; Mudambi S; Swetzig WM; Das GM; Shourideh M; Koochekpour S; Falzarano SM; Magi-Galluzzi C; Yadav N; Chen X; Lao C; Wang J; Billaud JN; Heemers HV
Elife; 2017 Aug; 6():. PubMed ID: 28826481
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
5. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
Wang G; Sadar MD
J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
[TBL] [Abstract][Full Text] [Related]
6. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
[TBL] [Abstract][Full Text] [Related]
7. Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention.
Dahiya UR; Heemers HV
Cells; 2022 Mar; 11(6):. PubMed ID: 35326387
[TBL] [Abstract][Full Text] [Related]
8. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
9. The androgen/androgen receptor axis in prostate cancer.
Bluemn EG; Nelson PS
Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor signaling regulates DNA repair in prostate cancers.
Polkinghorn WR; Parker JS; Lee MX; Kass EM; Spratt DE; Iaquinta PJ; Arora VK; Yen WF; Cai L; Zheng D; Carver BS; Chen Y; Watson PA; Shah NP; Fujisawa S; Goglia AG; Gopalan A; Hieronymus H; Wongvipat J; Scardino PT; Zelefsky MJ; Jasin M; Chaudhuri J; Powell SN; Sawyers CL
Cancer Discov; 2013 Nov; 3(11):1245-53. PubMed ID: 24027196
[TBL] [Abstract][Full Text] [Related]
11. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
Elbanna M; Heemers HV
Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
[TBL] [Abstract][Full Text] [Related]
12. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor structural and functional elements: role and regulation in prostate cancer.
Dehm SM; Tindall DJ
Mol Endocrinol; 2007 Dec; 21(12):2855-63. PubMed ID: 17636035
[TBL] [Abstract][Full Text] [Related]
14. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
15. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.
Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE
Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.
Shiota M; Song Y; Takeuchi A; Yokomizo A; Kashiwagi E; Kuroiwa K; Tatsugami K; Uchiumi T; Oda Y; Naito S
J Urol; 2012 Feb; 187(2):707-14. PubMed ID: 22177207
[TBL] [Abstract][Full Text] [Related]
17. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
Culig Z; Santer FR
Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor: past, present and future.
Schmidt LJ; Tindall DJ
Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
[TBL] [Abstract][Full Text] [Related]
19. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
20. Evolution of androgen receptor targeted therapy for advanced prostate cancer.
Wong YN; Ferraldeschi R; Attard G; de Bono J
Nat Rev Clin Oncol; 2014 Jun; 11(6):365-76. PubMed ID: 24840076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
